Ypsomed Holding AG

Common Name
Ypsomed Holding
Country
Switzerland
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
2,644
Ticker
YPSN
Exchange
SIX SWISS EXCHANGE
Description
Ypsomed Holding AG is a Swiss-based public company specializing in the development and manufacturing of medical devices for self-medication, with a core focus on injection and infusion systems. Servin...

Financial Statements of Ypsomed Holding

Below are the financial statements of Ypsomed Holding, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

All figures in millions of CHF20252024
Sales of goods and services
748.87a
548.46a
Cost of goods and services sold
-456.8a
-328.93a
Gross profit
292.07a
219.53a
Research and development expenses
-33.55a
-30.48a
Marketing and sales expenses
-89.74a
-78.88a
Administration expenses
-35.8a
-29.11a
Other operating income
1.08a
6.25a
Other operating expenses
-21.21a
-1.09a
Operating profit
112.85a
86.22a
Financial income
3.68a
4.84a
Financial expenses
-12.21a
-9.18a
Profit before income taxes
104.32a
81.87a
Income taxes
-16.81a
-3.51a
Net profit
87.5a
78.37a
Download Data

Verified Sources Behind Ypsomed Holding’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Ypsomed Holding’s data sources below and access millions more through our Disclosure Search.

a. Ypsomed Holding's Annual Report 2024
a. Ypsomed Holding's Annual Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?